AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes

Reuters

2025/05/15

<a href="https://laohu8.com/S/ABCL">AbCellera Biologics</a> Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes

AbCellera Biologics Inc. has announced that it has received a No Objection Letter from Health Canada, authorizing the company to initiate a Phase 1 clinical trial for ABCL635. This investigational antibody antagonist targets the neurokinin 3 receptor (NK3R) and is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, commonly known as hot flashes. The Phase 1 trial, scheduled to begin in the third quarter of 2025, will assess the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in healthy participants and postmenopausal women experiencing these symptoms. AbCellera aims to explore ABCL635 as a potential long-acting treatment option for this significant health issue affecting millions of women.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250516112255) on May 14, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2535880618"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535880618\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535880618?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535880618","market":"nz","top_or_hot":-1,"title":"AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AbCellera Biologics Inc. has announced that it has received a No Objection Letter from Health Canada, authorizing the company to initiate a Phase 1 clinical trial for ABCL635. This investigational antibody antagonist targets the neurokinin 3 receptor (NK3R) and is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, commonly known as hot flashes. The Phase 1 trial, scheduled to begin in the third quarter of 2025, will assess the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in healthy participants and postmenopausal women experiencing these symptoms. AbCellera aims to explore ABCL635 as a potential long-acting treatment option for this significant health issue affecting millions of women.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250516112255) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-15 05:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        AbCellera Biologics Inc. has announced that it has received a No Objection Letter from Health Canada, authorizing the company to initiate a Phase 1 clinical trial for ABCL635. This investigational antibody antagonist targets the neurokinin 3 receptor (NK3R) and is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, commonly known as hot flashes. The Phase 1 trial, scheduled to begin in the third quarter of 2025, will assess the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in healthy participants and postmenopausal women experiencing these symptoms. AbCellera aims to explore ABCL635 as a potential long-acting treatment option for this significant health issue affecting millions of women.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250516112255) on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL1QmYsZ:1","article_id":"2535880618","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535880618","pubTimestamp":1747256467,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AbCellera Biologics Inc. has announced that it has received a No Objection Letter from Health Canada, authorizing the company to initiate a Phase 1 clinical trial for ABCL635. This investigational antibody antagonist targets the neurokinin 3 receptor  and is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms  associated with menopause, commonly known as hot flashes. The Phase 1 trial, scheduled to begin in the third quarter of 2025, will assess the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in healthy participants and postmenopausal women experiencing these symptoms. AbCellera aims to explore ABCL635 as a potential long-acting treatment option for this significant health issue affecting millions of women.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","ABCL":"AbCellera Biologics","BK4535":"淡马锡持仓"},"translate_title":"AbCellera Biologics Inc.获得加拿大卫生部ABCL635治疗更年期潮热的1期试验授权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":0.9},"content_text":"AbCellera Biologics Inc. Receives Health Canada Authorization for Phase 1 Trial of ABCL635 to Treat Menopausal Hot Flashes\n    \n\n        AbCellera Biologics Inc. has announced that it has received a No Objection Letter from Health Canada, authorizing the company to initiate a Phase 1 clinical trial for ABCL635. This investigational antibody antagonist targets the neurokinin 3 receptor (NK3R) and is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, commonly known as hot flashes. The Phase 1 trial, scheduled to begin in the third quarter of 2025, will assess the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in healthy participants and postmenopausal women experiencing these symptoms. AbCellera aims to explore ABCL635 as a potential long-acting treatment option for this significant health issue affecting millions of women.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250516112255) on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}